At Usona, our exploration of psychedelic compounds is guided by discovery through scientific rigor. Our Medicinal Chemistry team continues publishing impactful research articles in collaboration with scientists around the globe.
Usona Publications
Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs
Samuel E. Williamson, Elise K. Burkhartzmeyer, Michael T. Faley, Rachel F. Ohana, Ilia A. Guzei, Mike Valley, James J. Cali, and Alexander M. SherwoodACS Chemical Neuroscience
DOI: 10.1021/acschemneuro.5c00879
In Vitro Psilocybin Synthesis by Co-Immobilized Enzymes
Schäfer, T., Sherwood, A., Kirkland, T., Krüger, T., Worbs, J., Kniemeyer, O., Gressler, M. and Hoffmeister, D. (2025), In Vitro Psilocybin Synthesis by Co-Immobilized Enzymes. Chem. Eur. J., 31: e202501037
Neuropharmacological Advances: Harnessing 5-HT2A Receptor Modulators and Psychoplastogens
Kargbo, R. B. ACS Med. Chem. Lett. 2024, DOI:org/10.1021/acsmedchemlett.4c00003
Psychedelic-like Activity of Norpsilocin Analogues
Alexander M. Sherwood, Elise K. Burkhartzmeyer, Samuel E. Williamson, Michael H. Baumann, and Grant C. Glatfelter ACS Chemical Neuroscience 2024 15 (2), 315-327
Perceptual Modifying Compounds and Their Potential Therapeutic Applications in Neuropsychiatric Disorders
Kargbo, R. B. ACS Med. Chem. Lett. 2024, 15 (1), 12–14
Small-Molecule Heterocyclic Compounds: Gq-Biased Agonists for the 5-HT2A Receptor in Neuropsychiatric Treatment
Kargbo, R. B. ACS Med. Chem. Lett. 2023, 14 (11), 1498–1500
Neurosteroids and Postpartum Depression: The Mechanism, Efficacy, and Approval of Brexanolone and Zurzuvae
Kargbo, R. B. ACS Med. Chem. Lett. 2023, 14 (10), 1326–1328
Microbiome: The Next Frontier in Psychedelic Renaissance
Kargbo, R. B. J. Xenobiot. 2023, 13 (3), 386-401.
Our Mission and Vision
Get more information about our Medicinal Chemistry team and our work with synthetic processes and psychedelic compounds.
